Literature DB >> 15592709

[Interdisciplinary cooperation in the treatment of complex patients with advanced testicular germ cell tumor].

A Heidenreich1, S Krege, M Flasshove.   

Abstract

Testicular germ cell tumors represent the classic example of a curable solid cancer even in the metastatic stage. Cure rates are as high as 95% and 80-85% in patients with good and intermediate prognosis; even in patients with poor prognosis cure rates of 50% have been achieved by interdisciplinary collaboration of all specialties involved in the management of testis cancer. Standardization of diagnosis and therapy should be further optimized due to the recently published interdisciplinary national and European guidelines. Besides realization of standardized guidelines, treatment of patients with extensive primary disease or recurrent germ cell tumors following standard therapy requires comprehensive knowledge in conservative and surgical management, which is basically only available at specialized cancer centers. Patients with complex findings, especially if associated with a poor prognosis according to IGCCCG, should be referred to specialized tertiary referral centers at a very early stage, since the cure rates depend not only on the consideration of guidelines but also on the expertise of the attending oncologist and surgeon. When treating these patients, one has to consider that inadequately administered chemotherapy (dosage, length of cycles, number of cycles) cannot be compensated for by surgery and that inadequately performed retroperitoneal lymphadenectomy or residual tumor resection cannot be compensated for by chemotherapy. In any case, suboptimal primary therapy will result in inferior cure rates and an unnecessarily increased mortality rate.

Entities:  

Mesh:

Year:  2004        PMID: 15592709     DOI: 10.1007/s00120-004-0728-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  33 in total

1.  Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

Authors:  K Fizazi; S Tjulandin; R Salvioni; J R Germà-Lluch; J Bouzy; D Ragan; C Bokemeyer; A Gerl; A Fléchon; J S de Bono; S Stenning; A Horwich; J Pont; P Albers; U De Giorgi; M Bower; A Bulanov; G Pizzocaro; J Aparicio; C R Nichols; C Théodore; J T Hartmann; H J Schmoll; S B Kaye; S Culine; J P Droz; C Mahé
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 3.  Treatment of early stage testicular seminoma.

Authors:  J Classen; R Souchon; T Hehr; M Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2001-08       Impact factor: 4.553

4.  Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.

Authors:  Axel Heidenreich; Carsten Ohlmann; Axel Hegele; Jörg Beyer
Journal:  Eur Urol       Date:  2005-01       Impact factor: 20.096

5.  Treatment of testicular cancer: a new and improved model.

Authors:  L H Einhorn
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

6.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group.

Authors:  Peter Albers; Lothar Weissbach; Susanne Krege; Sabine Kliesch; Michael Hartmann; Axel Heidenreich; Peter Walz; Markus Kuczyk; Rolf Fimmers
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

7.  [Testicular tumors. Mortality and recurrence after inadequate therapy].

Authors:  P Albers; K Dommer; S C Müller
Journal:  Urologe A       Date:  1998-11       Impact factor: 0.639

8.  The role of surgery in the combined management of metastases from malignant teratomas of testis.

Authors:  W F Hendry; A Barrett; T J McElwain; D M Wallace; M J Peckham
Journal:  Br J Urol       Date:  1980-02

9.  Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

Authors:  P J Loehrer; R Gonin; C R Nichols; T Weathers; L H Einhorn
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

10.  Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.

Authors:  S D Fosså; S P Stenning; A Gerl; A Horwich; P I Clark; P M Wilkinson; W G Jones; M V Williams; R T Oliver; E S Newlands; G M Mead; M H Cullen; S B Kaye; G J Rustin; P A Cook
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

View more
  3 in total

1.  [Optimizing treatment of advanced testicular germ cell tumors].

Authors:  D Pfister; B Brehmer; D Thüer; A Heidenreich
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

Review 2.  [Importance of pathology for therapy planning of testicular germ cell tumors].

Authors:  A Heidenreich; R Knüchel-Clarke; D Pfister
Journal:  Pathologe       Date:  2014-05       Impact factor: 1.011

Review 3.  [Stage-specific treatment for testicular germ cell tumours].

Authors:  A Heidenreich; C Bokemeyer; R Souchon
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.